ReviewCurrent opinion in pediatrics2015
Neurofibromatosis-related tumors: emerging biology and therapies.
Review in Current opinion in pediatrics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 74 citations in OpenAlex.
- Radiotherapy for low grade gliomas in children with neurofibromatosis type 1: when there is no other choice. Case Report.Frontiers in oncology · 2026Article
- Lip Schwannoma-A Rare Presentation in a Pediatric Patient: Case Report and a Literature Review.Diagnostics (Basel, Switzerland) · 2025Article
- Lifelong Management of Neurofibromatosis 1 Patients.Journal of Korean Neurosurgical Society · 2025Article
- Article
- Neurofibromatosis-Noonan syndrome and growth deficiency in an Iranian girl due to a pathogenic variant in NF1 gene.Human genomics · 2023Article
- Current Molecular Profile of Gastrointestinal Stromal Tumors and Systemic Therapeutic Implications.Cancers · 2022Review
- Neurofibromatosis in Children: Actually and Perspectives.Children (Basel, Switzerland) · 2022Review
- Phase 0 Clinical Trial of Everolimus in Patients with Vestibular Schwannoma or Meningioma.Molecular cancer therapeutics · 2021Article
- Surgical Management of Sporadic Peripheral Nerve Schwannomas in Adults: Indications and Outcome in a Single Center Cohort.Cancers · 2021Article
- Neurofibromatosis Type 1 with Concurrent Multiple Endocrine Disorders: Adenomatous Goiter, Primary Hyperparathyroidism, and Acromegaly.Internal medicine (Tokyo, Japan) · 2021Article
- Surgical management of peripheral nerve sheath tumours in children, with special consideration of neurofibromatoses.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2020Article
- Clinical spectrum of neurofibromatosis type 1 among children in a tertiary care center.Neurosciences (Riyadh, Saudi Arabia) · 2020Observational
- Early administration of imatinib mesylate reduces plexiform neurofibroma tumor burden with durable results after drug discontinuation in a mouse model of neurofibromatosis type 1.Pediatric blood & cancer · 2020Article
- Advanced pharmacological therapies for neurofibromatosis type 1-related tumors.Acta bio-medica : Atenei Parmensis · 2020Article
- Treatment, Resource Use and Costs Among Pediatric Patients with Neurofibromatosis Type 1 and Plexiform Neurofibromas.Pediatric health, medicine and therapeutics · 2020Article
- Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors.Journal of neuro-oncology · 2018Article
- Clinical and molecular characterization of 112 single-center patients with Neurofibromatosis type 1.Italian journal of pediatrics · 2018Article
- Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs' Revolution for Immunotherapy.International journal of molecular sciences · 2018Review
- Cell biology of glioblastoma multiforme: from basic science to diagnosis and treatment.Medical oncology (Northwood, London, England) · 2018Review
- Use of Surgical Laser for Excision of a Neurofibroma Associated With Neurofibromatosis Type-1.Journal of lasers in medical sciences · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
purpose of reviewOver the past decade, substantial insight into the biological function of the tumor suppressors neurofibromin (NF1) and Merlin (NF2) has been gained. The purpose of this review is to highlight some of the major advances in our understanding of the biology of neurofibromatosis type 1 (NF1) and neurofibromatosis type 2 (NF2) as they relate to the development of novel therapies for these disorders. RECENT
findingsThe development of increasingly sophisticated preclinical models over the recent years has provided the platform from which to rationally develop molecular targeted therapies for both NF1 and NF2-related tumors, such as within the Department of Defense-sponsored Neurofibromatosis Clinical Trials Consortium. SUMMARY: Clinical trials with molecular-targeted therapies have become a reality for neurofibromatosis patients, and hold substantial promise for improving the morbidity and mortality of individuals affected with these disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.